| Pharmaceutical Information |
| Drug Name |
Ceftobiprole |
| Drug ID |
BADD_D00404 |
| Description |
Ceftobiprole is a cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus. It was discovered by Basilea Pharmaceutica and is being developed by Johnson & Johnson Pharmaceutical Research and Development. Ceftobiprole is the first cephalosporin to demonstrate clinical efficacy in patients with infections due to methicillin-resistant staphylococci and, if approved by regulatory authorities, is expected to be a useful addition to the armamentarium of agents for the treatment of complicated skin infections and pneumonia. |
| Indications and Usage |
For the treatment of serious bacterial infections in hospitalised patients. |
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB04918
|
| KEGG ID |
D08885
|
| MeSH ID |
C443755
|
| PubChem ID |
135413542
|
| TTD Drug ID |
D0CI9T
|
| NDC Product Code |
Not Available |
| UNII |
5T97333YZK
|
| Synonyms |
ceftobiprole | BAL9141 | BAL 9141 |
|
| Chemical Information |
| Molecular Formula |
C20H22N8O6S2 |
| CAS Registry Number |
209467-52-7 |
| SMILES |
C1CNCC1N2CCC(=CC3=C(N4C(C(C4=O)NC(=O)C(=NO)C5=NSC(=N5)N)SC3)C(=O)O)C2=O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
